[REPL] ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Replimune Group, Inc. Investors

New York, New York--(Newsfile Corp. - July 25, 2025) - The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL) securities during the period of November 22, 2024 through July 21, 2025, inclusive ("the Class Period"). Investors have until September 22, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[LEARN MORE ABOUT THE CLASS ACTION]

On July 22, 2025, Replimune announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for its lead product RP1, in combination with immunotherapy drug nivolumab, for the treatment of advanced melanoma. In the CRL, the FDA indicated Replimune's IGNYTE trial is "not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness." On this news, the price of Replimune shares declined by $9.52 per share, or approximately 77.24%, to close at $2.81 per share on July 22, 2025.

According to the lawsuit, Replimune made false and/or misleading statements and/or failed to disclose that the Company overstated the IGNYTE trial's prospects, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled.

If you purchased or otherwise acquired Replimune securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT FORM]

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260163